Ning Lyu

10PUBLICATIONS
16CO-AUTHORS
Haematological tumoursHaematologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Free radical chemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 18, 2026
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.

|May 28, 2025
Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.

Qi-Feng Chen, Xiongying Jiang, Yue Hu

|Aug 06, 2024
Additional Hepatic Arterial Infusion Chemotherapy to Sorafenib Was Cost-Effective for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.

Qi-Feng Chen, Xiong-Ying Jiang, Yue Hu

|Mar 25, 2024
Recommended 10-Year Follow-Up Strategy for Small Hepatocellular Carcinoma After Radiofrequency Ablation: A Cost-Effectiveness Evaluation.

Qi-Feng Chen, Song Chen, Jun-Zhe Yi

|Mar 01, 2024
Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate.

Qi-Feng Chen, Song Chen, Minshan Chen

|Feb 26, 2024
Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma.

Meng He, Yongxiang Liu, Song Chen

Pageof 2

Frequent Collaborators

5 joint publications

Ming Zhao

2 joint publications

Song Chen

2 joint publications

Junzhe Yi

2 joint publications

Xiong-Ying Jiang